))
Highlights from ASH 2022
Manage episode 407440560 series 3560283
Content provided by Healio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Healio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition.
Mikkael A. Sekeres, MD, MS, chief of the division of hematology and professor of medicine at Sylvester Comprehensive Cancer Center and University of Miami Health System and chair of the ASH committee on communications, discusses some key take-home points from the Long COVID presentation. :00
Shakira J. Grant, MBBS, discusses multilevel interventions required to increase the rate at which Black individuals participate in hematology research studies. 3:44
Arushi Khurana, MBBS, reviews criteria used to disqualify patients from participating in front-line clinical trials, the acceptable ranges of which often prohibited Black and Hispanic patients from enrollment. 6:35
Tatyana Feldman, MD, discusses how the addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared active among patients with advanced-stage classical Hodgkin lymphoma. 9:32
Warren B. Fingrut, MD, reviews how hematopoietic stem cell transplant recipients of non-European ancestry had a significantly higher likelihood of receiving allogeneic grafts from HLA-mismatched donors than individuals of European ancestry. 12:02
Read the full coverage here:
Restrictive diet an 'unnecessary burden' for patients undergoing HSCT
Multilevel interventions needed to reduce racial disparities in clinical trial enrollment
Eligibility criteria more likely to exclude minorities from lymphoma clinical trials
Combination ‘promising’ for advanced classical Hodgkin lymphoma
Non-European HSCT recipients undergo more complex procedures with fewer resources
Disclosures:
Feldman reports consulting/advisory roles with, speakers bureau roles with or other financial relationships with AbbVie, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Genmab, Genomic Testing Cooperative, Janssen, Karyopharm Therapeutics, Kite Pharma, MorphoSys, Pharmacyclics, Secura Bio, Seagen and Takeda. Please see the abstract for all other researchers’ relevant financial disclosures.
Fingrut reports no relevant financial disclosures. Please see the abstract for all other researchers’ relevant financial disclosures.
Grant reports no relevant financial disclosures. Please see the abstract for all other researchers’ relevant financial disclosures.
Khurana reports no relevant financial disclosures.
12 episodes
Share
